The estimated Net Worth of Gene G. Kinney is at least $4.42 million dollars as of 17 May 2023. Gene Kinney owns over 45,000 units of Prothena plc stock worth over $1,209,607 and over the last 12 years he sold PRTA stock worth over $0. In addition, he makes $3,213,350 as President, Chief Executive Officer et Director at Prothena plc.
Gene has made over 15 trades of the Prothena plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 45,000 units of PRTA stock worth $1,341,450 on 17 May 2023.
The largest trade he's ever made was exercising 45,000 units of Prothena plc stock on 17 May 2023 worth over $1,341,450. On average, Gene trades about 7,984 units every 106 days since 2013. As of 17 May 2023 he still owns at least 57,793 units of Prothena plc stock.
You can see the complete history of Gene Kinney stock trades at the bottom of the page.
Dr. Gene G. Kinney Ph.D. serves as President, Chief Executive Officer, Director of the Company., is President, Chief Executive Officer, Director of the Company. Prior to that, he was our Chief Operating Officer for part of 2016, and prior to that he was our Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney was Vice President, Pharmacology and then Senior Vice President of Pharmacological Sciences at Elan Pharmaceuticals, Inc.; while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol-Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on our Board since 2016.
As the President, Chief Executive Officer et Director of Prothena plc, the total compensation of Gene Kinney at Prothena plc is $3,213,350. There are 1 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
Gene Kinney is 51, he's been the President, Chief Executive Officer et Director of Prothena plc since 2016. There are 15 older and 9 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
Gene's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... et Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: